UroGen Pharma (URGN) Research Hub

UroGen Pharma (URGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 42.31 USD (-5.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.29, market cap 2.09B. This hub links to the full technical, earnings and options research available for URGN.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close42.31 USD (-5.98%)
52-week range29.46 USD – 50.81 USD
Trend regimeRange
14-day RSI36 (Bearish)
Trailing P/E-15.29
Market cap2.09B
Dividend yield0.00%
Next earnings2026-08-06

Available research for URGN

Earnings

URGN earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -15.29. Updated 2026-07-23.

Options: Covered Call

Covered Call on URGN: how it works, illustrative setup around the real 42.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on URGN: how it works, illustrative setup around the real 42.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on URGN: how it works, illustrative setup around the real 42.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

URGN technical analysis: range, last 42.31 USD, RSI 36, 52w range 29.46 USD–50.81 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is URGN in?

UroGen Pharma (URGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is URGN in an uptrend or downtrend?

As of 2026-09-11, URGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is URGN's trailing P/E ratio?

URGN's trailing P/E is -15.29, with a market cap of 2.09B. See the earnings research page for full valuation detail.

When does URGN next report earnings?

URGN is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.28 USD.